Literature DB >> 19101898

Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.

Hassan Jamshidian1, Kianoush Kor, Mahmoud Djalali.   

Abstract

INTRODUCTION: The aim of this study was to determine the diagnostic value of urine nuclear matrix protein 22 (NMP22) level in detection of transitional cell carcinoma (TCC) of the bladder.
MATERIALS AND METHODS: A total of 76 patients with newly-diagnosed or recurrent TCC and 75 controls without urinary tract disorders participated in this study. A urine sample was obtained for measurement of the NMP22 level using the enzyme-linked immunoabsorbent assay. The resulted values were evaluated in comparison with the results of pathologic examination.
RESULTS: A total of 76 patients with TCC of the bladder and 75 volunteers without TCC were enrolled in the study. The mean level of urine NMP22 had an increasing trend associated with tumor grade (P = .01) and tumor stage (P < .001). In participants without TCC, the mean urinary NMP22 level was 5.48 +/- 6.34 U/mL, while this value was 25.01 +/- 35.33 U/mL in patients with TCC of the bladder (P < .001). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of urine NMP22 for detection of TCC were 75.5%, 86.7%, 85.1%, 77.4%, and 80.8%, respectively. The sensitivity of NMP22 in detecting stage Ta tumors appeared to be low (31.3%), but for grade 1 tumors, the sensitivity was 66.7%.
CONCLUSION: Measurement of urine NMP22 is a noninvasive, highly sensitive, and specific method for detecting TCC of the bladder and estimating its grade and stage. Further studies can be helpful to determine whether it can be used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101898

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  10 in total

1.  Urinary Biomarkers In Bladder Cancer.

Authors:  Matteo Costantini; Graziana Gallo; Giovanna Attolini
Journal:  Methods Mol Biol       Date:  2021

2.  eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation.

Authors:  Rita Spilka; Christina Ernst; Helmut Bergler; Johannes Rainer; Susanne Flechsig; Alexander Vogetseder; Eva Lederer; Martin Benesch; Andrea Brunner; Stephan Geley; Andreas Eger; Felix Bachmann; Wolfgang Doppler; Peter Obrist; Johannes Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2014-07-29       Impact factor: 6.730

3.  Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.

Authors:  Antara Datta; Martin E Adelson; Yakov Mogilevkin; Eli Mordechai; Abraham A Sidi; Jason P Trama
Journal:  BMC Cancer       Date:  2011-06-10       Impact factor: 4.430

4.  Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer.

Authors:  Thomas Reinert
Journal:  Adv Urol       Date:  2012-06-18

5.  The Diagnostic Value of Nuclear Matrix Proteins in Bladder Cancer in the Aspect of Environmental Risk from Carcinogens.

Authors:  Beata Szymańska; Ewa Sawicka; Anna Guzik; Romuald Zdrojowy; Anna Długosz
Journal:  Biomed Res Int       Date:  2017-08-08       Impact factor: 3.411

6.  Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens.

Authors:  Cheng-Han Tsai; Yi-Ting Chen; Ying-Hsu Chang; Chuen Hsueh; Chung-Yi Liu; Yu-Sun Chang; Chien-Lun Chen; Jau-Song Yu
Journal:  Oncotarget       Date:  2018-07-20

Review 7.  Genetic and molecular biology of bladder cancer among Iranian patients.

Authors:  Majid Mojarrad; Meysam Moghbeli
Journal:  Mol Genet Genomic Med       Date:  2020-04-06       Impact factor: 2.183

8.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27

Review 9.  Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.

Authors:  Iris Lodewijk; Marta Dueñas; Carolina Rubio; Ester Munera-Maravilla; Cristina Segovia; Alejandra Bernardini; Alicia Teijeira; Jesús M Paramio; Cristian Suárez-Cabrera
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

10.  The diagnostic and prognostic value of nuclear matrix protein 22 in bladder cancer.

Authors:  Xingxing Tang; Yudong Cao; Jia Liu; Shuo Wang; Yong Yang; Peng Du
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.